Clinical Trial Update: Sunitinib as a Second-line Treatment for Patients With Recurrent Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sunitinib as second-line therapy for recurrent small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Sutent (sunitinib)

Snippet

Sponsor: National Cancer Center, Korea | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED